GS-5319 Clinical Trials (2026): 1 Studies for Advanced Solid Tumor
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GS-5319 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Solid Tumor) and 178 total planned enrollment. 1 GS-5319 clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07128303 (May 2028).
Where to Participate: All GS-5319 Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting GS-5319trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT07128303 | Map |
| TX | START San Antonio | San Antonio78229 | NCT07128303 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT07128303 | Map |
GS-5319 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting GS-5319 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07128303 | Study of GS-5319 in Adults With Solid Tumors | P1 | Advanced Solid Tumor | 178 | Aug 2025 |
All GS-5319 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07128303 | Study of GS-5319 in Adults With Solid Tumors | P1 | recruiting | 178 | Gilead Sciences | Aug 2025 |
GS-5319 clinical trials: frequently asked questions
- How many GS-5319 clinical trials are there?
- 1 GS-5319 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GS-5319 clinical trials recruiting in 2026?
- Yes — 1 GS-5319 trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is GS-5319 being studied for?
- GS-5319 is being studied for Advanced Solid Tumor. The trials are grouped by indication on this page.
- What phase is GS-5319 in?
- GS-5319 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors GS-5319 clinical trials?
- The lead sponsor across the most GS-5319 trials is Gilead Sciences. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GS-5319as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: